Eight Unanswered Questions about Psychiatric Research in Minnesota

The wait has been exhausting, but it is possible that a flicker of light may finally shine on the dark recent history of psychiatric research at the University of Minnesota. Given these upcoming investigations of psychiatric research at the University of Minnesota, the time is right to look back at some of the disturbing, unanswered questions that have emerged over the past several years.
Full Article

Categorized In:

Spearheading Doctors and the Re-introduction of Electroconvulsive Therapy for Children

As a mother of 3 children, grandmother of 3, I was both shocked and disturbed to read that ECT was being promoted as a safe treatment for children and a viable option in healthcare. For I know that ECT causes fits to the brain, memory loss, headaches and trauma, to some if not many. I know this because I’ve heard it from people who have received ECT voluntarily. They tell me that it caused them to lose “good” memories, eg of holidays, and some have said it made no difference to their mental wellbeing, in terms of being able to come off psychiatric drugs or in dealing with low mood. They talk of having “maintenance” shock treatment and of not being allowed hospital discharge until agreeing to have it.
Full Article

Categorized In:

Science and Pseudoscience in Psychiatric Training: What Psychiatrists Don’t Learn and What Psychiatrists Should Learn

Evidence based care is supposed to drive up standards, ensure uniformity, establish best practice, guide clinicians and protect patients. This should be celebrated. Instead, evidence-based mental health is openly disparaged, and when psychiatrists don’t get the results they want, they ignore them, suppress them, or denounce them. These attitudes have repercussions on the training of psychiatrists.
Full Article

Categorized In:

Are You Ready for Multiple Lawsuits By Victims of Psychiatric Misconduct?

Professor Leigh Turner of the University of Minnesota Center for Bioethics blasts the Board of Regents for ignoring psychiatric research abuse.
Full Article

Categorized In:

Markingson Case Supporters: Please Join Our Call-In Campaign

Patient advocates and bioethicists have launched a call-in campaign demanding action on psychiatric research abuse at the University of Minnesota.
Full Article

Categorized In:

Have You Ever Taken an Experimental Antipsychotic Called Bifeprunox?

In 2004, a patient was given an experimental antipsychotic called bifeprunox and died of hepatorenal failure nine days later. But the sponsor apparently did not investigate the death for three years. In late 2007 the sponsor issued a safety alert and suspended all bifeprunox studies. This is where things get interesting.
Full Article

Categorized In:

CAFÉ Study: Real Science or Marketing Exercise?

I received the following question from a reader regarding the controversial CAFÉ – Comparisons of Atypicals in First Episode of Psychosis – study. (This was the study in which Dan Markingson committed suicide.) “It appears that there was no head-to-head with a control group taking a placebo pill. Nor was there a control group featuring ‘old’ types of ‘antipsychotic’. If that was the case then it is very poor study . . . what on earth can you hope to show from the data?” I started to write a response, but the subject is complex, and my response became the following article.
Full Article

Categorized In:

Investigate the Markingson Suicide? Not So Fast, Says University President

Responding to a letter signed by 175 scholars asking for an inquiry into the death of Dan Markingson at the University of Minnesota, the Faculty Senate voted to investigate clinical research at the university. But the university president says the Markingson case will not be part of the investigation. What is he trying to hide?
Full Article

Categorized In:

KMSP-TV Investigative Report on Psychiatric Research Abuse at the University of Minnesota

For a scathing, 11-minute overview of the death of Dan Markingson at the University of Minnesota, and new allegations of coercion into psychiatric clinical trials, you can’t do much better than this excellent investigative report by Jeff Baillon.
Full Article

Categorized In:

As Lawyers and Bureaucrats Delay,
The Body Count Rises

It took over twenty years for the state medical board to sanction a Minnesota psychiatrist who was responsible for the deaths and injuries of 46 patients. Today, in the Markingson case, it looks as if history is repeating itself. How many patients die while bureaucrats delay?
Full Article

Categorized In:

The Slow Torture of Mary Weiss

Dan Markingson was floridly psychotic and unable to give informed consent when University of Minnesota researchers coerced him into an industry-funded drug study. His mother, Mary Weiss, warned the researchers that Dan was in danger of killing himself, but she was ignored. Dan committed a violent suicide in 2004. Last week, after fighting the university and research regulators for nine years, Mary suffered a severe stroke. Her struggle for justice is in serious danger.
Full Article

Categorized In:

The Drugs Don’t Work,
and Bipolar Disorder is the Proof

The world appears to be going mad in its efforts to hold back the tide of human distress by pharmaceutical means. Because the drugs don’t work we may be put on cocktails of anti-psychotics, anti-depressants and mood stabilisers, with benzos thrown in. This can cause havoc with our state of mind, in my experience. And in reality isn’t anti- anything.
Full Article

Categorized In:

Tapering Off Medications When “Symptoms Have Remitted”:
Does That Make Sense?

While a 2-year outcome study by Wunderink, et al. has been cited as evidence that guided discontinuation of antipsychotics for people whose psychosis has remitted results in twice as much “relapse,” a not-yet-published followup of that study, extending it to 7 years using a naturalistic followup, finds that the guided discontinuation group had twice the recovery rates, and no greater overall relapse rate (with a trend toward the medication group having more relapse.)
Full Article

Categorized In:

How Much can a Psychiatrist Charge to Visit With a Dead Research Subject?

At the University of Minnesota, the answer is apparently $1,446. If harmless clerical errors were to blame for oddities like this, that fact should be easy to clarify simply by looking at the relevant documents.  But if there are systematic issues with the administration of clinical trials that makes it possible to bill for a visit with a dead subject, those issues would be important for other universities and private trial sites as well. 
Full Article

Categorized In:

“They Need to be Held Accountable”

Psychiatrists at the University of Minnesota forced a young man into a profitable study of antipsychotic drugs over the objections of his mother, who desperately warned that his condition was deteriorating and that he was in danger of killing himself. On May 8, 2004, Mary Weiss’ only son, Dan Markingson, committed suicide. A petition to the governor of Minnesota now asks for an investigation.
Full Article

Categorized In:

Components for a Good Neuroleptic Withdrawal Program

The United States desperately needs good programs to help people withdraw from neuroleptics, that is, antipsychotic drugs. From all I have seen and heard, there aren’t any — none at least that can reputably claim to get good results on a fairly consistent basis. Again and again I find myself challenged to envision such a program, and in reply to the challenge I have broken down this hypothetical program into various components.
Full Article

Categorized In:

And That’s the News from the Department of Psychiatry

In the business of clinical trials, the most valuable commodities are the research subjects. Filling clinical trials is hard, and filling them quickly is even harder. That’s why in 2000 a clinical investigator told the HHS Office of the Inspector General that research sponsors were looking for three things from research sites: “No. 1—rapid enrollment. No. 2 — rapid enrollment. No. 3 — rapid enrollment.”
Full Article

Categorized In:

“Baby Cry Too Much?”

This is the second in my new series, “Haiku for social change”, the first having appeared on my own blog page. Since this piece is about pharmacology and psychopharmacology, I think MIA is a good home for it.
Full Article

Categorized In:

How to Get Away with Academic Misconduct at the University of Minnesota

In early 2009, antipsychotic fraud was making headlines.  Eli Lilly had announced in January that it would plead guilty to charges that it had illegally marketed Zyprexa. The company agreed to pay a record-breaking $1.42 billion in penalties. Meanwhile, AstraZeneca …
Full Article

Categorized In:

We Are All Adam Lanza’s Mother (& other things we’re not talking about)

I do not understand how we can continue to avoid the conversation about psychiatric medications and their role in the violence that is affecting far too many of our children, whether Seung-Hui Cho, Eric Harris, Kip Kinkel, or Jeff Weise (all of whom were either taking or withdrawing from psychotropic medications) or the scores of children and adults they have killed and harmed. It is not clear what role medications played in the Newtown tragedy, though news reports are now suggesting there is one.
Full Article

Categorized In:

The Road to Perdition

The recent research scandals out of the University of Minnesota’s Department of Psychiatry may be alarming, but they are not new. Back in the 1990s, when the university was working its way towards a crippling probation by the National Institutes of Health (for yet another episode of misconduct (this time in the Department of Surgery), the Department of Psychiatry hosted two spectacular cases of research wrongdoing, both of which resulted in faculty members being disqualified from conducting research by the FDA.
Full Article

Categorized In:

The University of Minnesota was not Involved? Some Further Thoughts on the “Corrective Action” Against Jean Kenney in the Markingson Case

The suicide of Dan Markingson at the University of Minnesota has brought notoriety to the CAFÉ study and its site investigators, Stephen Olson and Charles Schulz. But the “corrective action” recently issued by the Minnesota Board of Social Work against the CAFÉ study coordinator, Jean Kenney, has raised another disturbing question.
Full Article

Categorized In:

“Do We Have to Wait Until He Kills Himself or Someone Else Before Anyone Else Does Anything?”

In the “agreement for corrective action” against CAFE study coordinator Jean Kenney last week, the Board of Social Work cited Kenney’s failure to respond to “alarming voicemail messages” from family members of Dan Markingson. Presumably, the Board is referring to a message left by his mother, Mary Weiss, which warned, “Do we have to wait until he kills himself or someone else before anyone else does anything?” The failure of Kenney and Stephen Olson to take the warnings of Mary Weiss seriously has been one of the most disturbing aspects of this case. In a deposition for the lawsuit filed by Weiss, Kenney was questioned about her response. Here is an excerpt. (The initial questions come from Gale Pearson, an attorney for Mary Weiss.)

Full Article

Categorized In:

“I Was Just Following Orders”: a Seroquel Suicide, a Study Coordinator, and a “Corrective Action”

Out here in Minnesota, where the snow is gently falling, many of us are hunched over our computers, puzzling over a document just posted by the state Board of Social Work. It concerns the death of Dan Markingson (or as the document calls him, “Client #1”). Markingson, of course, was a young man under a commitment order who was coerced into a profitable Seroquel marketing study at the University of Minnesota over the objections of his mother, and whose condition spiraled downward until he committed suicide.
Full Article

Categorized In:

New Research Project to be Funded by the Foundation for Excellence in Mental Health Care

Over the last 30 years Dr. Martin Harrow, Ph.D., has collected data from over 1000 interviews with people who have lived experience with mental illness. His research has been the basis for a number of papers delineating the effect of medications on those he interviewed. Further analysis of the data will answer several questions that provide the basis for a better understand of the long term effects of anti-psychotics on the treatment of schizophrenia.
Full Article

Categorized In: